Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This article was originally published in The Tan Sheet
Executive Summary
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
You may also be interested in...
Supreme Court Ruling In Wyeth Case May Make FDA More Cautious
How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies
Supreme Court Ruling In Wyeth Case May Make FDA More Cautious
How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies
Supreme Court Ruling In Wyeth Case May Make FDA More Cautious
How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies